EOLS
Evolus, Inc.
$5.80
+0.26
(+4.69%)
Mkt Cap
382.29M
Volume
545,991
52W Range
3.86-10.2
Sector
Healthcare
Beta
1.32
EPS (TTM)
-0.67
P/E Ratio
-8.31
Revenue (TTM)
301.79M
Rev Growth (5Y)
+39.4%
EPS Growth (5Y)
N/A
Company Description
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 297.18M | 266.27M | 202.09M | 148.62M | 99.67M | 56.54M | 34.92M | 0 | 0 | 0 | 0 |
| Net Income | (51.64M) | (50.42M) | (61.69M) | (74.41M) | (46.81M) | (163.01M) | (90.03M) | (46.87M) | (4.48M) | (20.07M) | (31.11M) |
| EPS | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.19 | -1.08 | -1.67 |
| Free Cash Flow | (50.72M) | (19.47M) | (35.63M) | (87.85M) | (34.36M) | (61.01M) | (97.95M) | (25.68M) | (13.04M) | (13.27M) | (36.38M) |
| FCF / Share | -0.79 | -0.31 | -0.63 | -1.57 | -0.69 | -1.81 | -3.47 | -1.05 | -0.55 | -0.71 | -1.96 |
| Operating CF | (42.27M) | (18.00M) | (34.01M) | (84.91M) | (33.39M) | (57.87M) | (93.38M) | (25.67M) | (13.04M) | (13.27M) | (36.38M) |
| Total Assets | 225.87M | 232.57M | 189.00M | 177.98M | 257.48M | 209.07M | 240.44M | 171.84M | 152.23M | 77.50M | 81.30M |
| Total Debt | 155.00M | 129.98M | 126.55M | 74.42M | 74.74M | 138.32M | 96.55M | 16.90M | 211.33M | 59.76M | 46.17M |
| Cash & Equiv | 53.83M | 86.95M | 62.84M | 53.92M | 146.26M | 102.56M | 109.89M | 93.16M | 0 | 0 | 4.00M |
| Book Value | (23.11M) | 5.52M | (20.69M) | 18.50M | 81.88M | (72.96M) | 79.46M | (123.03M) | (75.54M) | (7.11M) | 12.00M |
| Return on Equity | N/A | -9.13 | N/A | -4.02 | -0.57 | N/A | -1.13 | N/A | N/A | N/A | -2.59 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 73.14M | 90.30M | 68.97M | 69.39M | 68.52M | 78.95M | 61.09M | 66.91M | 59.33M | 61.00M | 50.02M | 49.35M |
| Net Income | (10.67M) | 130,000 | (15.74M) | (17.14M) | (18.89M) | (6.79M) | (19.17M) | (11.35M) | (13.11M) | (11.83M) | (16.92M) | (18.14M) |
| EPS | -0.16 | 0.00 | -0.24 | -0.27 | -0.30 | -0.11 | -0.30 | -0.18 | -0.22 | -0.21 | -0.30 | -0.32 |
| Free Cash Flow | (11.64M) | 10.66M | (16.83M) | (27.06M) | (17.49M) | 3.45M | (7.13M) | (7.72M) | (11.41M) | 452,000 | (1.46M) | (13.32M) |
| FCF / Share | -0.18 | 0.17 | -0.26 | -0.42 | -0.27 | 0.06 | -0.11 | -0.12 | -0.19 | 0.01 | -0.03 | -0.23 |
| Operating CF | (9.95M) | 12.83M | (14.67M) | (24.79M) | (15.63M) | 4.81M | (5.72M) | (6.47M) | (10.62M) | 813,000 | (924,000) | (13.31M) |
| Total Assets | 220.65M | 225.87M | 219.00M | 228.80M | 213.36M | 232.57M | 229.61M | 233.77M | 226.18M | 189.00M | 167.97M | 168.98M |
| Total Debt | 164.90M | 155.00M | 154.89M | 154.91M | 130.20M | 129.98M | 129.88M | 126.75M | 126.65M | 126.55M | 101.44M | 96.82M |
| Cash & Equiv | 49.79M | 53.83M | 43.52M | 61.74M | 67.89M | 86.95M | 85.03M | 93.67M | 96.96M | 62.84M | 38.69M | 41.70M |
| Book Value | (28.78M) | (23.11M) | (28.76M) | (18.65M) | (6.60M) | 5.52M | 5.89M | 19.31M | 18.44M | (20.69M) | (19.37M) | (6.96M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -1.23 | -3.25 | -0.59 | -0.71 | N/A | N/A | N/A |
EOLS News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
Evolus to Report First Quarter Financial Results on May 4, 2026
JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS